Rekvina Laboratories Intrinsic Value
Rekvina Laboratories intrinsic value. Rekvina Laboratories (VINRKLB) median intrinsic value is ₹15.15 from 1 valuation models (range ₹15–₹15), vs current price ₹50.50 — -70.0% downside (Trading Above Calculated Value), margin of safety -100.0%. Compare with Rekvina Laboratories valuation methods to assess whether the stock is under or overvalued.
VINRKLB Valuation Methods Summary — DCF, Graham Number & P/E
Rekvina Laboratories intrinsic value across 1 models vs current price ₹50.50 — upside/downside and value range per method. Read Rekvina Laboratories dividend payments for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Revenue Multiple Method | revenue | ₹15.15 | ₹13.63 - ₹16.67 | -70.0% | Revenue/Share: ₹6.67, P/S: 2.0x |
VINRKLB Intrinsic Value vs Market Price — All Valuation Models
Rekvina Laboratories fair value range ₹15–₹15 vs current market price ₹50.50 across 1 valuation models. For current market price and key ratios, visit VINRKLB stock price BSE.
VINRKLB Intrinsic Value Analysis — Undervalued or Overvalued?
Rekvina Laboratories median intrinsic value ₹15.15, current price ₹50.50 — Trading Above Calculated Value by 70.0%, margin of safety -100.0%.
What is the intrinsic value of VINRKLB?
Based on our comprehensive analysis using 1 different valuation methods, the estimated intrinsic value of Rekvina Laboratories (VINRKLB) is ₹15.15 (median value). With the current market price of ₹50.50, this represents a -70.0% variance from our estimated fair value.
The valuation range spans from ₹15.15 to ₹15.15, indicating ₹15.15 - ₹15.15.
Is VINRKLB undervalued or overvalued?
Based on our multi-method analysis, Rekvina Laboratories (VINRKLB) appears to be trading above calculated value by approximately 70.0%.
VINRKLB Financial Health — Key Ratios vs Industry Benchmarks
Rekvina Laboratories financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Operating Margin | -19.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 2.00x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
VINRKLB Cash Flow Quality — Operating & Free Cash Flow
Rekvina Laboratories operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹-1 Cr | ₹-1 Cr | Negative Cash Flow | 3/10 |
| March 2025 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |